Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VRXA vs YDES: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

YDES Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–1 Matrix Metrics)

YDES Overall Winner 6-Pillar Tally: VRXA 1 – 2 YDES (3 Tie) Matrix Metrics: VRXA 1 – 7 YDES

As of Nov 20, 2026, YD Bio Limited (YDES) is the stronger overall head-to-head candidate over VRXA (VRXA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). VRXA carries a Unified Composite Score of 41.6/100 (SELL) at $1.04 (N/M Forward P/E, N/A operating margin), whereas YDES carries 49.0/100 (HOLD) at $4.83 (N/M Forward P/E, -528.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRXA vs YDES
VRXA US Equity
VRXA
Institutional Equity
$1.04
+0.97% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.16β · 104% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 30.0 Fund 41.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $1.04 · SMA50: $1.17
YDES NASDAQ Head-to-Head Winner
YD Bio Limited Ordinary Shares
Services-Medical Laboratories
$4.83
+5.92% 1D
Market Cap $323.0M
TTM Revenue $1.2M
Forward P/E N/M
Beta / 30D Vol -0.07β · 139% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 31.0 Fund 35.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.6 · SMA20: $5.73 · SMA50: $5.60

6-Pillar Scorecard Institutional Category Breakdown (VRXA 1 – 2 YDES)

Columns: Metric · VRXA · YDES
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale YDES
Revenue Growth (YoY) N/A +314.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $1.2M
Market Cap N/A $323.0M
3. Profitability & Quality YDES
Gross Margin N/A 29.6%
Operating Margin N/A -528.7%
Net Profit Margin N/A 24.7%
Return on Equity (ROE) N/A -42.7%
4. Balance Sheet & Cash Flow VRXA
Cash Generation (TTM) N/A -$6.3M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.06 Book/Sh · -42.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRXA (1) vs YDES (7)
Institutional Metric VRXA YDES Criterion Row Edge
Market Capitalization
Scale
N/A $323.0M Larger Scale YDES
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +314.9% Higher Growth YDES
Operating Margin (TTM)
Profitability
N/A -528.7% Higher Margin YDES
Net Profit Margin
Profitability
N/A 24.7% Higher Margin YDES
Return on Equity (ROE)
Capital Efficiency
N/A -42.7% Higher ROE YDES
52-Week Range Position
Momentum
0% ($1–$27) 22% ($2–$16) Stronger Trend YDES
Beta / 30D Volatility
Risk Regime
1.16β · 104% Vol -0.07β · 139% Vol Lower Realized Risk VRXA
Unified Institutional Score
Composite Signal
41.6 / 100 (SELL) 49.0 / 100 (HOLD) Higher Composite YDES
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 29.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$6.3M EBITDA ($0.06 Book/Sh · -42.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YDES +12.95 pp
VRXA: +0.97% · YDES: +13.92%
3M Horizon YDES +45.22 pp
VRXA: -41.57% · YDES: +3.65%
6M Horizon YDES +144.42 pp
VRXA: -95.8% · YDES: +48.62%
1Y Horizon YDES +144.42 pp
VRXA: -95.8% · YDES: +48.62%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRXA vs YDES. Trailing 12-month operating profitability (VRXA N/A vs YDES -528.7%) and valuation multiples (VRXA N/M vs YDES N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VRXA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
YDES ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.2M
Gross Margin29.6%
Op. Margin-528.7%
ROE / Fwd P/E-42.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRXA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRXA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
YDES UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YDES Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRXA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
YDES Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $323.0M market capitalization and -528.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRXA vs YDES Key Questions & Quantitative Answers

As of Nov 20, 2026, YD Bio Limited (YDES) is the stronger overall head-to-head candidate over VRXA (VRXA) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). VRXA carries a Unified Composite Score of 41.6/100 (SELL) at $1.04 (N/M Forward P/E, N/A operating margin), whereas YDES carries 49.0/100 (HOLD) at $4.83 (N/M Forward P/E, -528.7% operating margin). Technically, VRXA sits in a Neutral phase (RSI 46.0, UNCLASSIFIED options structure) and YDES sits in a Neutral phase (RSI 43.6, UNCLASSIFIED options structure).

YDES leads the Growth & Scale pillar: VRXA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with YDES at +314.9% YoY revenue growth and +0.0% YoY earnings growth on $1.2M TTM revenue (29.6% gross margin, -528.7% operating margin). On trailing 12-month operating scale, VRXA generates N/A in USD-normalized revenue versus $1.2M for YDES. In operating R&D and SG&A reinvestment, VRXA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for YDES.

VRXA and YDES trade at balanced relative valuation multiples. VRXA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas YDES trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRXA (N/A ROE) versus YDES (-42.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VRXA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.16β · 104% Vol realized risk). By comparison, YDES carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 139% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.